Viking Therapeutics thinks it has rumbled a raid on its nonalcoholic steatohepatitis (NASH) trade secrets. In a lawsuit, the San Diego-based biotech has accused China’s Ascletis BioScience of using ...

Viking Therapeutics, Inc. (VKTX) closed at $27.88 in the latest trading session, marking a +1.86% move from the prior day. This move outpaced the S&P 500's daily gain of 0.06%. Meanwhile, the Dow ...

Shares of Viking Therapeutics plummeted more than 43% Tuesday after the company revealed poorer-than-expected mid-stage trial data for its experimental weight-loss pill, joining Eli Lilly with similar ...

At $24 versus the $89 analyst average price target, Viking trades at a steep discount. While some targets will likely be revised lower, the size of the decline appears excessive for a company with no ...

Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...